{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pre-filled+Syringes+%28PFS%29",
    "query": {
      "intervention": "Pre-filled Syringes (PFS)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 59,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pre-filled+Syringes+%28PFS%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-13T14:34:16.665Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07007091",
      "title": "A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Risankizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 260,
      "start_date": "2025-06-12",
      "completion_date": "2026-01-15",
      "has_results": false,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-09-13T14:34:16.665Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Grayslake, Illinois • Las Vegas, Nevada + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Grayslake",
          "state": "Illinois"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07007091"
    },
    {
      "nct_id": "NCT03099980",
      "title": "Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "secukinumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2016-07-11",
      "completion_date": "2019-01",
      "has_results": false,
      "last_update_posted_date": "2019-06-03",
      "last_synced_at": "2026-09-13T14:34:16.665Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03099980"
    },
    {
      "nct_id": "NCT07673627",
      "title": "ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AChR-Ab Seropositive Generalized Myasthenia Gravis",
        "Myasthenia Gravis (MG)",
        "MG - Myasthenia Gravis",
        "gMG"
      ],
      "interventions": [
        {
          "name": "Empasiprubart IV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo IV",
          "type": "OTHER"
        },
        {
          "name": "Efgartigimod PH20 SC PFS",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2026-07-10",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-13T14:34:16.665Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Amherst, New York • Chattanooga, Tennessee",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Amherst",
          "state": "New York"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07673627"
    },
    {
      "nct_id": "NCT06307626",
      "title": "A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "Efgartigimod PH20 SC",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo PH20 SC",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "OTHER"
      ],
      "sponsor": "argenx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2024-03-28",
      "completion_date": "2026-02-12",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-09-13T14:34:16.665Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Mission Hills, California • Rancho Cordova, California + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Rancho Cordova",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06307626"
    },
    {
      "nct_id": "NCT01849497",
      "title": "Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Hypercholesterolemia",
        "Mixed Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab Pre-filled Syringe",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Evolocumab AI/pen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 149,
      "start_date": "2013-04-18",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2018-11-29",
      "last_synced_at": "2026-09-13T14:34:16.665Z",
      "location_count": 21,
      "location_summary": "Encino, California • Thousand Oaks, California • Ventura, California + 17 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Westlake Village",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01849497"
    },
    {
      "nct_id": "NCT02996019",
      "title": "A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Etrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Auto-Injector (AI)",
          "type": "DEVICE"
        },
        {
          "name": "Prefilled Syringe With Needle Safety Device (PFS-NSD)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 180,
      "start_date": "2016-12-07",
      "completion_date": "2018-04-09",
      "has_results": false,
      "last_update_posted_date": "2018-12-03",
      "last_synced_at": "2026-09-13T14:34:16.665Z",
      "location_count": 4,
      "location_summary": "Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02996019"
    },
    {
      "nct_id": "NCT06741657",
      "title": "A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Litifilimab",
          "type": "DRUG"
        },
        {
          "name": "AI",
          "type": "DEVICE"
        },
        {
          "name": "OBI",
          "type": "DEVICE"
        },
        {
          "name": "PFS",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 404,
      "start_date": "2025-01-02",
      "completion_date": "2026-03-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-09-13T14:34:16.665Z",
      "location_count": 2,
      "location_summary": "Las Vegas, Nevada • Austin, Texas",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06741657"
    },
    {
      "nct_id": "NCT05069896",
      "title": "A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Mirikizumab Prefilled Syringe",
          "type": "DRUG"
        },
        {
          "name": "Mirikizumab Autoinjector",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 237,
      "start_date": "2021-10-05",
      "completion_date": "2022-06-22",
      "has_results": true,
      "last_update_posted_date": "2025-03-04",
      "last_synced_at": "2026-09-13T14:34:16.665Z",
      "location_count": 3,
      "location_summary": "Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05069896"
    },
    {
      "nct_id": "NCT03970837",
      "title": "Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "GSK3196165 (Otilimab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1764,
      "start_date": "2019-06-05",
      "completion_date": "2023-01-18",
      "has_results": true,
      "last_update_posted_date": "2023-11-30",
      "last_synced_at": "2026-09-13T14:34:16.665Z",
      "location_count": 64,
      "location_summary": "Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 58 more",
      "locations": [
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Poway",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03970837"
    },
    {
      "nct_id": "NCT01863732",
      "title": "Extension in AS: Sustainability of Benefits, Safety and Tolerability",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Spondylitis, Ankylosing"
      ],
      "interventions": [
        {
          "name": "Secukinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Pbo)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 274,
      "start_date": "2013-11-06",
      "completion_date": "2018-03-16",
      "has_results": true,
      "last_update_posted_date": "2019-07-30",
      "last_synced_at": "2026-09-13T14:34:16.665Z",
      "location_count": 5,
      "location_summary": "Portland, Oregon • Duncansville, Pennsylvania • Jackson, Tennessee + 2 more",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        },
        {
          "city": "Jackson",
          "state": "Tennessee"
        },
        {
          "city": "Kingsport",
          "state": "Tennessee"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01863732"
    }
  ]
}